ecancermedicalscience

Case Report

Pegylated Liposomal Doxorubicin (PLD): enhanced skin toxicity in areas of vitiligo

9 Dec 2008
Y Yuan, SJ Orlow, J Curtin, A Downey, F Muggia

Pegylated liposomal doxorubicin (PLD, Doxil, Caelyx) is widely used for the treatment of ovarian cancer. It is a stable formulation encapsulating doxorubicin in a ‘Stealth’ (i.e., pegylated) liposome with a half-life of about 72 hours. This drastically altered pharmacology confers on it a considerably lower risk of cardiotoxicity, no acute emesis, and near absence of alopecia or problems with extravasation necrosis. On the other hand, PLD's dose-limiting toxicity is cutaneous. Since the original phase I report, cutaneous toxicities reported with PLD fall into four common categories: the well known hand-foot syndrome (also called palmoplantar erythrodysesthesia, or PPE), a diffuse follicular rash, intertrigo-like eruption, and hyperpigmentation including melanotic macules.

Related Articles

Muisi A Adenekan, Joseph B Minari, Ayodeji Adefemi, Gbenga Olorunfemi, Ayomide I Fayinto, Adebayo Sekumade, Temitope V Adekanye, Adeyemi A Okunowo, Kehinde S Okunade
Pambinkavil Sivaraman Raji, Anitha Thomas, Vinotha Thomas, Anjana Joel, Dhanya Susan Thomas, Rachel G Chandy, Ajit Sebastian, Abraham Peedicayil
Solomon Kibudde, Awusi Kavuma, Bonny Abal, Moses Fredrick Katumba, Cissy Bangidde Namutale, Daniel Kanyike, Israel Luutu
Abideen A Olayiwola, Yusuf A Oshodi, Oluwarotimi I Akinola, Adekunbiola A Banjo, Kabiru A Rabiu, Ayokunle M Olumodeji